# Schizophrenia

Manage schizophrenia with measurement-based antipsychotic treatment, early detection of nonresponse and nonadherence, adverse-effect-directed drug selection, and timely clozapine for treatment resistance, persistent suicidality, or aggression. Long-acting formulations can strengthen relapse prevention when oral adherence is unreliable.

**Clinical question:** How should clinicians select, monitor, and escalate antipsychotic treatment for schizophrenia, including treatment-resistant illness?

Updated: 2026-08-21T02:07:37.809447+00:00

## What matters in practice
- After an inadequate antipsychotic response, distinguish insufficient exposure or adherence from true treatment resistance before serial medication changes; long-acting injectable formulations can address an adherence-driven relapse pattern.[6][10][16]
- Clozapine is the only antipsychotic with regulatory approval for treatment-resistant schizophrenia and remains the evidence-based standard for this population.[1][12][21][23]
- Do not delay clozapine in established treatment resistance: later initiation has been associated with lower efficacy, while clozapine has advantages for positive symptoms, relapse or hospitalization, suicidal behavior, aggression, and functioning.[12]
- Select non-clozapine antipsychotics chiefly by prior response, comorbidity, formulation preference, and predictable adverse-effect tradeoffs rather than expecting large average efficacy differences.[10]
- Use every antipsychotic encounter, particularly long-acting injectable visits, to monitor weight and cardiometabolic risk; schizophrenia is associated with markedly shortened life expectancy, largely from chronic physical disease.[14]

## Identify immediate risk and reassess the diagnostic trajectory

Stabilization and diagnostic revision should proceed alongside symptom treatment.

At each acute presentation, determine whether suicidal behavior, persistent aggressive behavior, inability to maintain safety, or recurrent relapse is driving the episode. Persistent substantial suicide-attempt or suicide risk despite other treatments is a specific circumstance in which clozapine is recommended; the same applies to substantial persistent aggressive behavior despite other treatments.[8][21]

Reassess the longitudinal diagnosis when the course becomes affective, substance-related, medically atypical, or inconsistent with prior episodes. First-episode psychosis diagnoses are usually stable within the schizophrenia spectrum (pooled stability 0.93, 95% CI 0.89-0.97), but about 5% transition to an affective-spectrum psychosis; ongoing diagnostic review therefore changes treatment planning when mood syndromes become syndromically prominent.[9]

Document a baseline symptom and function measure that can be repeated after each treatment change. PANSS is a standardized 30-item clinician-rated measure of general schizophrenia symptoms; pair symptom tracking with direct assessment of medication exposure, adverse effects, suicidality, substance use, and functional deterioration rather than interpreting persistent psychosis as drug failure alone.[17][7]
- Escalate the safety plan when relapse is accompanied by suicidal ideation, prior attempts, hopelessness, severe illness, or medication nonadherence; these factors track with poorer outcomes and greater suicide risk.[7]
- Treat diagnostic uncertainty as active follow-up work: changing from a schizophrenia-spectrum to affective-spectrum diagnosis occurs in a clinically meaningful minority after first-episode psychosis.[9]

*Clinical patterns that should redirect the next management step.*

| Observed pattern | Interpretation | Next action |
| --- | --- | --- |
| Persistent suicidality despite prior treatments | Clozapine-specific treatment opportunity.[8][21] | Evaluate candidacy for clozapine rather than continuing nonspecific antipsychotic substitutions.[8][21] |
| Persistent aggression despite prior treatments | Clozapine is recommended when aggressive behavior remains substantial.[8] | Consider clozapine after assessing safety, treatment history, and capacity for monitoring.[8][21] |
| Repeated relapse with unreliable oral exposure | Apparent nonresponse may be adherence-related rather than pharmacologic treatment resistance.[6][10][16] | Offer an acceptable long-acting injectable formulation and monitor outcomes longitudinally.[6][16] |
| Prominent emergent affective syndrome during follow-up | A minority of first-episode cases are later classified within the affective spectrum.[9] | Reassess diagnosis and align pharmacotherapy with the revised syndrome.[9] |

## Choose an antipsychotic by exposure reliability and adverse-effect vulnerability

For most patients, selection is individualized rather than hierarchy-driven.

For nonrefractory schizophrenia, use a prior effective and tolerated agent when available. When selecting a new agent, weigh expected efficacy against the patient’s history of metabolic dysregulation, extrapyramidal symptoms, hyperprolactinemia, cardiovascular risk, medication acceptability, preferred formulation, comorbid illness, and prior response. Outside clozapine in refractory illness, sufficiently large and consistent efficacy differences among antipsychotics are not established; adverse-event differences often drive the practical choice.[10]

Consider a long-acting injectable antipsychotic when missed oral doses, recurrent relapse, uncertain exposure, or patient preference makes sustained oral treatment unreliable. Long-acting injectable strategies can improve adherence and reduce relapse, but they do not remove the need to evaluate metabolic, motor, and endocrine adverse effects.[6][16]

Do not equate a second-generation antipsychotic with low cardiometabolic risk. Antipsychotics, particularly second-generation agents, are associated with metabolic dysregulation, cardiovascular adverse effects, and type 2 diabetes risk. Olanzapine may precipitate metabolic syndrome early in treatment, whereas clozapine carries substantial long-term metabolic burden; treatment selection should therefore incorporate baseline physical risk and the feasibility of ongoing monitoring.[11][14]
- Prior intolerable extrapyramidal symptoms or hyperprolactinemia should favor an agent with a lower expected burden for those outcomes; receptor binding and pharmacokinetics inform dosing and switching decisions.[10][11]
- Prior rapid weight gain, diabetes, dyslipidemia, or central obesity should shift the benefit-risk discussion away from higher metabolic-burden options when clinically feasible.[11][14]
- A long-acting injectable is an adherence intervention, not evidence of treatment resistance; establish whether relapse followed insufficient exposure before declaring an oral agent ineffective.[6][10][16]

### Monitoring at routine visits

Use routine psychiatric visits and injectable administration encounters to detect cardiometabolic toxicity early. Follow body weight and central adiposity, blood pressure, glucose intolerance or diabetes, and dyslipidemia because these are the clinical components of metabolic syndrome and mediate cardiovascular and cerebrovascular risk.[14]

Assess motor adverse effects with a structured examination when antipsychotic exposure changes or abnormal movements emerge. The Abnormal Involuntary Movement Scale is a standardized 7-item assessment for dyskinesia and can support longitudinal detection of tardive phenomena.[17]
- New metabolic toxicity should prompt a drug-specific benefit-risk reassessment rather than passive observation, especially with olanzapine or clozapine exposure.[11][14]
- New dyskinesia or other clinically important motor effects should trigger review of dose, agent, and cumulative antipsychotic exposure.[10][17]

*Antipsychotic selection framework based on clinically meaningful tradeoffs.*

| Clinical priority | Selection implication | Monitoring emphasis |
| --- | --- | --- |
| Reliable oral adherence and prior tolerability | Continue or select according to prior response and adverse-effect vulnerability.[10] | Track symptoms, function, metabolic parameters, and motor effects.[10][14][17] |
| Missed oral doses or relapse linked to nonadherence | Discuss long-acting injectable treatment to improve continuity of exposure.[6][16] | Use administration encounters for symptom, relapse, metabolic, and motor surveillance.[14][16][17] |
| High metabolic vulnerability | Avoid assuming class-wide metabolic equivalence; individualize away from higher-risk options when benefits do not outweigh risk.[11][14] | Weight, central adiposity, blood pressure, glucose, and lipids.[14] |
| Established treatment resistance | Move to clozapine rather than repeated routine antipsychotic substitution.[1][12][21][23] | Hematologic monitoring and assessment for serious clozapine adverse effects.[12][21] |

## Separate pseudo-resistance from treatment-resistant schizophrenia

The next intervention depends on whether treatment exposure was adequate.

When psychosis persists, reconstruct each prior antipsychotic trial before assigning treatment resistance: agent, dose trajectory, treatment duration, adherence, formulation, adverse effects, relapse timing, and reason for discontinuation. Pharmacologically informed, measurement-based prescribing integrates acute symptom goals with long-term functional goals and reduces the risk of misclassifying inadequate exposure or an intolerable regimen as pharmacologic failure.[10]

A recurrent pattern of missed medication, inconsistent follow-up, or relapse after stopping oral treatment should lead first to an adherence-focused intervention, including a long-acting injectable option when acceptable. Sustained antipsychotic therapy significantly reduces relapse risk after first-episode psychosis, although published discontinuation relapse estimates vary widely across studies.[23]

If persistent symptoms occur despite adequate prior antipsychotic treatment and adherence has been addressed, treat the patient as having likely treatment-resistant schizophrenia and evaluate for clozapine. Clozapine remains the gold-standard treatment in treatment-resistant schizophrenia and is the only antipsychotic with regulatory approval for this indication.[1][12][21][23]
- Do not postpone clozapine solely by cycling through additional standard antipsychotics once treatment resistance is established; delayed initiation has been associated with reduced efficacy.[12]
- Keep the treatment target explicit: persistent positive symptoms, recurrent hospitalization, suicidal behavior, aggression, adherence failure, and unacceptable adverse effects require different next steps.[7][8][10][12]
- Use shared decision-making around formulation, adverse-effect priorities, monitoring burden, and functional goals because acceptability affects persistence with treatment.[6][10][21]

*Response-based escalation in schizophrenia.*

| Treatment-course finding | Most likely management problem | Decision |
| --- | --- | --- |
| Relapse after missed oral doses | Insufficient medication exposure.[6][10] | Address adherence; offer a long-acting injectable formulation when suitable.[6][16] |
| Persistent psychosis with uncertain prior dose, duration, or adherence | Inadequately characterized treatment trial.[10] | Clarify exposure and optimize a measurement-based treatment plan before labeling resistance.[10] |
| Persistent symptoms after adequate antipsychotic treatment | Treatment-resistant schizophrenia.[1][12][21][23] | Initiate a clozapine candidacy and monitoring evaluation.[12][21] |
| Substantial suicide or aggression risk despite other treatments | Clozapine-responsive high-risk phenotype.[8][21] | Prioritize clozapine evaluation alongside immediate safety management.[8][21] |

## Use clozapine promptly when its benefit outweighs monitoring burden

Clozapine is a distinct treatment pathway, not simply another routine switch.

Offer clozapine for treatment-resistant schizophrenia after confirming that persistent illness is not principally due to nonadherence, inadequate prior exposure, or a revised diagnosis. Compared with other dopamine receptor-blocking antipsychotics in treatment-resistant schizophrenia, clozapine has demonstrated superior positive-symptom reduction and advantages in relapse or hospitalization, suicidal behaviors, aggressive behavior, substance use, functioning, and mortality outcomes.[12]

Discuss clozapine earlier rather than framing it as a last resort. Up to 40% of patients may meet treatment-resistant schizophrenia criteria, yet clozapine is prescribed to fewer than 10% of people with schizophrenia worldwide; delayed use is associated with reduced efficacy.[12]

Before and during initiation, plan the monitoring infrastructure rather than relying on patient recall. Clozapine requires hematologic examinations, and therapeutic drug level monitoring may sometimes be needed. Its adverse-effect burden includes potentially life-threatening myocarditis, reported particularly in the first 8 weeks, as well as metabolic toxicity; these risks justify structured surveillance and rapid assessment of compatible symptoms.[11][12][21]
- Clozapine is FDA approved for treatment-resistant schizophrenia and is not a first-line antipsychotic because of its adverse-effect and monitoring burden.[21]
- Persistent suicidal behavior or aggression despite other treatments can justify clozapine even when symptom response history does not fit a simple sequential-switch framework.[8][21]
- Avoid using a lower tardive-dyskinesia risk profile as a reason to overlook hematologic, cardiac, and metabolic monitoring requirements.[11][21]

### Monitoring priorities during clozapine treatment

Maintain required hematologic monitoring and ensure that the patient can reliably complete testing before initiation. Clozapine-associated care also creates frequent clinical contact, which can support assessment of adherence, relapse, suicidality, metabolic change, and functional recovery.[12][21]

During the first 8 weeks, assess urgently for symptoms that could represent myocarditis because early clozapine-induced myocarditis can progress to fulminant heart failure. Throughout treatment, monitor metabolic risk because clozapine is strongly associated with metabolic dysregulation and has been linked with metabolic syndrome in approximately 30% after 10 years of treatment.[11][14]
- Use structured movement assessment when clinically indicated; AIMS supports detection of dyskinesia over time.[17]
- Reassess treatment success beyond psychosis: hospitalization, suicidal behavior, aggression, substance use, functional status, and treatment persistence are clinically relevant clozapine outcomes.[12]

*Clozapine decision and surveillance priorities.*

| Decision point | Action | Clinical rationale |
| --- | --- | --- |
| Treatment-resistant schizophrenia | Evaluate and initiate clozapine when monitoring can be delivered.[1][12][21] | Clozapine is the evidence-based standard and regulatory-approved treatment for this indication.[1][12][21] |
| Substantial persistent suicidality or aggression after other treatments | Prioritize clozapine evaluation with concurrent safety management.[8][21] | These are guideline-supported clozapine indications.[8] |
| Initiation and early treatment | Maintain hematologic monitoring and assess urgently for possible myocarditis symptoms, especially in the first 8 weeks.[11][12][21] | Myocarditis can be life-threatening and may progress to fulminant heart failure.[11] |
| Long-term treatment | Monitor metabolic syndrome components and functional outcomes.[12][14] | Clozapine has substantial metabolic burden but can improve relapse, hospitalization, and functional outcomes.[12][14] |

## Make maintenance care a structured relapse and physical-health program

The maintenance plan should detect relapse, adverse effects, and disengagement before crisis-level deterioration.

Schedule follow-up around the individual’s relapse pattern and treatment delivery route. At each visit, record current psychotic symptoms, negative symptoms when relevant, functional change, medication exposure, adverse effects, suicidal thinking, substance use, and hospital or emergency utilization. PANSS can quantify overall symptom change, while the Brief Negative Symptom Scale assesses domains such as apathy and diminished expression when negative symptoms are a treatment target.[17]

Treat physical-health surveillance as part of antipsychotic effectiveness, not as a separate preventive task. People with schizophrenia have an estimated 13- to 15-year shorter life expectancy than healthy controls, predominantly related to chronic physical conditions including coronary heart disease and type 2 diabetes. Monitor central obesity, dyslipidemia, glucose intolerance, and hypertension because they define metabolic syndrome and predict cardiovascular, diabetes, and cerebrovascular risk.[14]

When metabolic toxicity, motor toxicity, or poor adherence threatens persistence, revise the regimen before relapse occurs. A switch to a lower metabolic-risk option, a long-acting injectable to improve exposure continuity, or clozapine for genuine treatment resistance should be selected according to the driver of treatment failure rather than a uniform escalation sequence.[6][10][12][13]
- Use a repeated scale rather than impression alone when determining whether a medication change produced meaningful improvement.[17]
- Ask directly about missed doses and injection attendance; relapse prevention depends on sustained exposure, and long-acting injectable treatment can make medication delivery observable.[6][16][23]
- Involve the patient in formulation and adverse-effect tradeoffs; acceptability is a determinant of adherence and outcomes.[6][10][21]

*Maintenance visit targets in schizophrenia.*

| Domain | Practical assessment | Action if abnormal |
| --- | --- | --- |
| Symptoms and function | Repeat PANSS; add BNSS when negative symptoms are clinically central.[17] | Confirm exposure, reassess diagnosis and target symptoms, then adjust therapy according to response pattern.[9][10][17] |
| Adherence and relapse | Review missed oral doses, delayed injections, relapse symptoms, hospital use, and treatment acceptability.[6][16][23] | Offer or optimize a long-acting injectable when unreliable oral exposure is the principal barrier.[6][16] |
| Metabolic risk | Assess weight or central adiposity, blood pressure, glucose intolerance, and dyslipidemia.[14] | Reassess antipsychotic benefit-risk balance and intensify management of identified cardiometabolic disease.[11][14] |
| Motor adverse effects | Perform structured assessment, including AIMS when dyskinesia is suspected or being followed.[17] | Review dose and agent selection in the context of motor burden and psychiatric response.[10][17] |

## References
1. Clozapine and treatment-resistant schizophrenia: efficacy ... — www.thelancet.com — https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(25)00032-X/abstract
2. a systematic review and network meta-analysis — www.thelancet.com — https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00223-8/fulltext
3. Treatment paradigms for treatment-resistant schizophrenia — www.thelancet.com — https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(24)00173-1/abstract
4. Standard versus reduced dose of antipsychotics for relapse ... — www.thelancet.com — https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(21)00078-X/abstract
5. DSM: Diagnostic and Statistical Manual of Mental ... — jamanetwork.com — https://jamanetwork.com/journals/jama/fullarticle/193533
6. Nature Index Antipsychotic Treatment Strategies in Schizophrenia — www.nature.com — https://www.nature.com/nature-index/topics/l4/antipsychotic-treatment-strategies-in-schizophrenia
7. Effectiveness of antipsychotic medication in patients with schizophrenia in a real world retrospective observational study in Ethiopia | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-025-85832-3
8. Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review | Translational Psychiatry — www.nature.com — https://www.nature.com/articles/s41398-021-01613-2
9. Diagnostic Stability of ICD/DSM First Episode Psychosis ... — academic.oup.com — https://academic.oup.com/schizophreniabulletin/article/42/6/1395/2399275
10. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0924933810717016
11. Comparing the pharmacology and pharmacokinetics of antipsychotics: Choosing an antipsychotic and dosing a long-acting injectable — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0924977X23000901
12. Clozapine: past, present and future - Correll - 2025 - World Psychiatry — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/wps.21335
13. The association of metabolic syndrome and long acting injectable antipsychotics: A systematic review — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0213616322000027
14. The association of metabolic syndrome and long acting injectable ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0213616322000027
15. The Effectiveness of Guideline Implementation... : Medical ... — journals.lww.com — https://journals.lww.com/lww-medicalcare/Fulltext/2008/07000/The_Work_Limitations_Questionnaire.7.aspx?Ppt=Article%7Clww-medicalcare%3A2008%3A07000%3A00007%7C10.1097%2Fmlr.0b013e3181653d43%7C
16. Differentiating aspects of oral and long-acting injectable ... — journals.lww.com — https://journals.lww.com/intclinpsychopharm/_layouts/15/oaks.journals/downloadpdf.aspx?an=00004850-202511000-00009
17. Overcoming psychomotor slowing in psychosis (OCoPS-P) - A 3 ... — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/50/NCT03921450/Prot_SAP_000.pdf
18. Study Details | NCT06072898 | A Randomized Neuroimaging Trial of Psilocybin in Depression | ClinicalTrials.gov — clinicaltrials.gov — https://clinicaltrials.gov/study/NCT06072898
19. Exercise and markers of medial temporal health in youth at ... — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/99/NCT02155699/Prot_SAP_000.pdf
20. Study Details | NCT03348761 | rTMS Response Trajectories in Depression | ClinicalTrials.gov — clinicaltrials.gov — https://clinicaltrials.gov/study/NCT03348761
21. Clozapine - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK535399
22. Paliperidone | Drug Lookup | Pediatric Care Online — publications.aap.org — https://publications.aap.org/pediatriccare/drug-monograph/18/6041/Paliperidone
23. Prevalence of treatment resistance and clozapine use in early intervention services - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC7576650
24. Evaluating the Role of Clozapine in Treatment-Resistant Schizophrenia: A Narrative Synthesis of Clinical, Economic, and Quality-of-Life Outcomes — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12607604

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.